Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Dermatologic 1

Conditions

Melanoma 24Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Carcinoma, Renal Cell 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Colorectal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Neuroblastoma 4Neoplasms 4Lymphoma 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Esophageal Neoplasms 3Colonic Neoplasms 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Interleukin-2 × Clear all
NCT06640582 2024-11-05

BAH2472

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Meningioma

NCT03297463 2018-08-01

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Masonic Cancer Center, University of Minnesota

Phase 1/2 Withdrawn
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡